CLOSEOUT LETTER
Laboratoires Clarins MARCS-CMS 568157 —
- Reference #:
- 3002759467
- Product:
- Drugs
- Recipient:
-
Recipient NameMr. Jonathan Zrihen
-
Recipient TitleCEO
- Laboratoires Clarins
- Clarins Group
12, avenue de la Porte-des-Ternes
75017 Paris
France
- Issuing Office:
- Center for Drug Evaluation and Research | CDER
United States
Dear Mr. Zrihen:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-19-20 dated April 23, 2019.
Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.
The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Philip Kreiter
Compliance Officer
Division of Drug Quality II
CC:
Ms. Cécile Mansuy
Operations Director
Laboratoires Clarins
5 rue Ampére
95300 Pontoise
France